StandoutStocks.com: StandoutStocks.com "Stocks that Standout" today are: CETG, CHKT, CICN, CLXS, EREI

Aug 07, 2008 (M2 PRESSWIRE via COMTEX) -- EREI | Quote | Chart | News | PowerRating -- StandoutStocks.com "Stocks that Standout" today are: Capital City Energy Group, Inc. (OTCBB: CETG), Chemokine Therapeutics Corp. (TSX: CTI/OTCBB: CHKT), Cicero Inc. (OTCBB: CICN), Collexis Holdings Inc. (OTCBB: CLXS), EAGLE ROCK ENTERPRISES, INC. (PINKSHEETS: EREI), and Proudly Introducing Proprietary Push Technology (PPT).

The Newest and Revolutionary Technology for Increasing Investor Visability.

REAL Awareness for REAL Companies.

Click below for a full demonstration.

http://newmediaadvisors.info/newmedia.swf

Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at www.Standoutstocks.com

Aug 06, 2008 -- Capital City Energy Group, Inc. (OTCBB: CETG | Quote | Chart | News | PowerRating) announced today that it has applied for listing of its shares of common stock on the American Stock Exchange LLC (AMEX). Although no assurances can be given that the Company's common stock will be accepted for listing, the Company believes that it meets the quantitative standards for original listing under the standards listed in the Amex Company Guide.

"The submission of our application to the AMEX is an important step in gaining greater exposure in the investment community," said Capital City Chief Executive Officer Timothy W. Crawford. "We believe that the listing of our common stock on the AMEX will enhance shareholder liquidity and value, building on the Company's accomplishments in the short time it has been public."

About Capital City Energy Group, Inc.

Based in Columbus, Ohio, Capital City is a diversified oil and natural gas company with three separate divisions. Capital City is evolving from being an innovative leader in the design, management and sponsorship of retail and institutional direct participation energy programs to become one of the few vertically integrated independent oil & natural gas companies. Their strategy is to continue to grow a portfolio of core areas that provide growth opportunities through grass-roots drilling, operating, service companies, acquisitions and fund management.

"Investing in America's Energy Future"

Aug 06, 2008 -- Chemokine Therapeutics Corp. ("Chemokine Therapeutics" or the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular disease today announced that research results were presented yesterday by the laboratory of Dr. Danny R. Welch, President of the Metastasis Research Society and Professor of Pathology, Cell Biology and Pharmacology, University of Alabama at Birmingham, at the Joint Metastasis Research Society (MRS) - American Association for Cancer Research (AACR) Conference on Metastasis held in Vancouver, B.C., Canada.

The data demonstrated in pre-clinical models that CTCE-9908 decreased the spread of breast cancer to the ovary by about half, decreased the size of tumors in the femur, and decreased the number of tumors in the heart and other organs examined. The overall amount of tumor in these studies was reduced by 50%.

"These positive results from Dr. Welch, a leader in the metastasis field, provide further validation of the anti-metastasis activity of CTCE-9908," stated Dr. Donald Wong, Vice President of Drug Development.

Researchers at the University of Alabama at Birmingham have been studying the ability of CTCE-9908, lead drug candidate from Chemokine Therapeutics, to inhibit metastasis of human breast cancer in pre-clinical models as part of a collaborative research effort with the Company.

About CTCE-9908

CTCE-9908 is a peptide analog of the chemokine SDF-1, and an antagonist of its receptor, CXCR4. SDF-1 is the only known naturally occurring chemokine that binds to CXCR4, which is present on many cancer cells as well as cancer support cells such as cells making up new blood vessels. This binding process is believed to be critical to cell migration. The anti-migration property of CTCE-9908 is pivotal in not only reducing recruitment of support cells that allow survival and growth of the primary tumor, but also metastasis (or spread) of cancer cells to distant locations in the body, where they form secondary tumors. Approximately 90% of cancer deaths are due to metastasis and disease progression. We believe that CTCE-9908 has the potential to shrink the primary tumor and delay the occurrence of new tumors due to its anti-angiogenic properties and anti-metastatic activity.

About Chemokine Therapeutics Corp. (TSX: CTI)(OTCBB: CHKT)

Chemokine Therapeutics is a product-focused biotechnology company developing drug candidates in the field of chemokines. Chemokines are a class of signaling proteins that play a critical role in the growth, differentiation, and maturation of cells necessary for fighting infection as well as tissue repair and regeneration. Chemokines also have an important role in cancer metastasis and growth. Chemokine Therapeutics is a leader in research in the field of chemokines and has several products in various stages of development.

Aug 6, 2008 -- Cicero Inc. (OTCBB: CICN), a leading provider of desktop integration and automation solutions, today announced that Cicero has received a 2008 TMC Labs Innovation Award from Technology Marketing Corporation's Customer Interaction Solutions magazine, the leading publication covering CRM, call centers and teleservices since 1982.

Cicero's proven technology provides a framework for rapidly integrating and enabling applications, allowing companies to improve end user productivity and elevate the customer experience. Cicero automates workflow and provides a cost-effective way to organize diverse business applications within a consistent, task-oriented desktop. Using Cicero, organizations can quickly integrate and enable business applications such as Software as a Service CRM, Web, Windows, and legacy. Cicero can also be used to create new composite applications, integrate web services, leverage information from third party applications, and extend the functionality of legacy systems in support of a Service-Oriented Architecture. Additionally, Cicero allows you to consolidate data, streamline business processes, enforce rules and compliance, and add additional functionality such as single sign-on without having to purchase new applications.

"Cicero has clearly demonstrated to the staff of TMC Labs that their product is truly innovative in the CRM and contact center industries. Cicero has made significant contributions in the advancement of this industry," said Nadji Tehrani, founder and chairman of TMC, and publisher of Customer Interaction Solutions. "We're proud to reward this outstanding accomplishment with a TMC Labs Innovation Award this year."

"Cicero deserves this great honor for creating a ground-breaking solution. Cicero has demonstrated raw innovation and offers unique features," added Tom Keating, CTO and TMC Labs Editorial Director. "I look forward to seeing other innovative solutions from Cicero as they continue to contribute to the future of the CRM and call center marketplace."

The TMC Labs Innovation Awards honor products that demonstrate raw innovation, unique features, and significant contributions toward improving communications technology. The TMC Labs Innovation Awards are not granted only to the best-selling products, but instead to those representing a significant contribution to the industry.

The TMC Labs 2008 Innovation Award highlights will be published in the September and October 2008 issues of Customer Interaction Solutions magazine.

About Cicero Inc

Cicero Inc. provides software integration solutions for contact centers and other complex information environments. Cicero solutions align underlying technology with business processes, streamline user interactions, improve total productivity, assure completeness and compliance, reduce turnover, and raise knowledge-worker morale and effectiveness.

Patented Cicero technology quickly and non-invasively integrates disparate applications on the desktop. Cicero integration produces results in weeks, and ROI can be achieved in months. Cicero commits to results which are impossible for invasive, server-side strategies and technologies.

Cicero's technology serves more than 50,000 knowledge workers at Merrill Lynch, Nationwide Financial, and other companies, large and small. In one recent implementation, Cicero integrated eight applications for nine hundred agents' desktops in only seven weeks to reduce average call times by approximately 40 seconds. Results also include improved customer service and a $1+ million per year operating cost reduction.

Cicero and Cicero Studio are trademarks of Cicero Inc. and/or its affiliates. Other company names and/or products are for identification purposes and are the property of, and may be trademarks of, their respective owners.

About Customer Interaction Solutions

Since 1982, Customer Interaction Solutions (CIS) magazine has been the voice of the call/contact center, CRM and teleservices industries. CIS magazine has helped the industry germinate, grow, mature and prosper, and has served as the leading publication in helping these industries that have had such a positive impact on the world economy to continue to thrive. Through a combination of outstanding and cutting-edge original editorial, industry voices, in-depth lab reviews and the recognition of the innovative leaders in management and technology through our highly valued awards, Customer Interaction Solutions strives to continue to be the publication that holds the quality bar high for the industry.

About TMC

Technology Marketing Corporation (TMC) is an integrated global media company helping our clients build communities in print, in-person and online. TMC publishes Customer Interaction Solutions, INTERNET TELEPHONY, Unified Communications, and IMS Magazine. TMC is also the first publisher to test new products in its own on-site laboratories, TMC Labs. TMCnet, TMC's Web site, is the leading source of news and articles for the communications and technology industries. TMCnet is read by nearly one million U.S. visitors according to Quantcast and by two to three million unique visitors each month worldwide, according to Webtrends. In addition, TMC produces INTERNET TELEPHONY Conference & EXPO, Call Center 2.0 Conference and Communications Developer Conference.

Aug 06, 2008 -- Lawriter, LLC a subsidiary of Collexis Holdings Inc. (OTCBB: CLXS | Quote | Chart | News | PowerRating) announced today the development of the first professional social network exclusively for law students. The site www.CasemakerX.com was showcased in Beta format at the American Association of Law Librarians Conference in Portland in July. A full launch is expected in early fall 2008 to coincide with the incoming class of new law students. Along with the social networking site, CasemakerX will provide free access to the Casemaker Suite of Applications for the U.S. law student community.

"CasemakerX is an exciting new legal information product that law students and faculty will find useful," said Duncan Alford, associate dean and director of the law library at the University Of South Carolina School Of Law. "The social networking portion of CasemakerX is reminiscent of LinkedIn, but with the electronic content of primary federal and state law. The upcoming introduction of legal thesaurus searching will make the searching capabilities even more sophisticated and the success of the Collexis search engine and fingerprinting technology in medical research shows exciting promise for legal research."

CasemakerX is a free service for law students supported by the Casemaker Bar Consortium and its 475,000 attorney members across the U.S. Law students, faculty and law librarians can sign up for the site and register from accredited Law Schools. Once a profile is created, users are networked by areas like corresponding law school, fields of interest, graduation year, etc. Users can also enjoy a host of social networking components including capabilities like blogging, instant messaging, photo sharing, job postings, video streaming via YouTube(TM), and iPhone plug-ins. Lawriter's Casemaker suite of legal discovery products is available on the site and includes a library of over 12 Million documents in federal and state case law. The site also includes the recently released Casemaker Medical application, with full text search of over 15 Million biomedical abstracts.

"We are pleased to host this community for the next generation of attorneys," said Steve Newsom, general manager for Lawriter. "Our mission is to help law students succeed - connecting with their peers, their teachers, and the external attorney community to advance their education and career goals."

About the Casemaker Bar Consortium

The Casemaker Bar Consortium consists of twenty-eight State bars that are in strategic partnership with Lawriter, who provide the Bar's members their Casemaker suite of discovery products for primary case law research, supplemental publications and continuing education materials. They are: Alabama, Alaska, Colorado, Connecticut, Georgia, Hawaii, Idaho, Indiana, Kansas, Kentucky, Maine, Massachusetts, Mississippi, Nebraska, New Hampshire, New Mexico, North Carolina, North Dakota, Ohio, Oregon, Rhode Island, South Carolina, Texas, Utah, Vermont, Washington, West Virginia, and Wyoming.

About Collexis Holdings, Inc.

Collexis Holdings, Inc., a leading developer of semantic search and knowledge discovery software, is headquartered in Columbia, South Carolina (USA) with major operations in Cincinnati, Ohio, Geldermalsen, the Netherlands and Cologne, Germany. Collexis now offers the world's first pre-populated scientific social network for life science researchers, www.biomedexperts.com. Collexis' proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, Websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis' current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; Dana-Farber Cancer Institute, the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTCBB).

Aug 05, 2008 -- EAGLE ROCK ENTERPRISES, INC. (PINKSHEETS: EREI | Quote | Chart | News | PowerRating) (EAGLE ROCK) is pleased to announce a strategic partnership with the BLIND VENDORS OF ILLINOIS. John Gordon, President of the Illinois Committee of Blind Vendors for 12 years and First Vice President of the Randolph Sheppard Organization stated, "The purchasing economics of the NATIONAL BLIND ENTERPRISES CO-OP (a subsidiary of EAGLE ROCK) allows our vendors to maximize their sales volume potential and coordinate their inventory needs."

Gordon further added, "The quarterly reports from our distributors will reflect significant increases for the major brands such as M&M, Pepsi, Frito-lay, Kraft, Kellogg's and others involved in EAGLE ROCK's national Plan-O-Gram program."

About Standoutstocks.com

Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies. Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at www.Standoutstocks.com and select the "join now" button.

Join us at www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.standoutstocks.com/disclaimer.aspx

CONTACT: Standoutstocks.com e-mail: info@standoutstocks.com WWW: http://www.standoutstocks.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index